AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01242371 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Identical-appearing Placebo
Description: Probiotic identical placebo 1 tablet by mouth daily
Study NCT01195207 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CNTO 3157 or placebo
Description: 0.003 mg/kg CNTO 3157 or placebo infusion
Study NCT01195207 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CNTO 3157 or placebo
Description: 0.03 mg/kg CNTO 3157 or placebo infusion
Study NCT01195207 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CNTO 3157 or placebo
Description: 10 mg/kg CNTO 3157 or placebo infusion
Study NCT01195207 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CNTO 3157 or placebo
Description: 0.01 mg/kg CNTO 3157 or placebo infusion
Study NCT01195207 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CNTO 3157 or placebo
Description: 1 mg/kg CNTO 3157 or placebo infusion
Study NCT01195207 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CNTO 3157 or placebo
Description: 3 mg/kg CNTO 3157 or placebo infusion
Study NCT01195207 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CNTO 3157 or placebo
Description: 0.3 mg/kg CNTO 3157 or placebo infusion
Study NCT01195207 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CNTO 3157 or placebo
Description: 0.1 mg/kg CNTO 3157 or placebo infusion
Study NCT02827032 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MobiusHD™
Description: The MobiusHD device is a self-expanding nitinol implant that is delivered intravascularly to the internal carotid sinus via the delivery catheter.
Study NCT01407276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omarigliptin
Description: Single oral dose of 3 mg (3 x 1-mg capsules)
Study NCT04370535 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: cellulose
Description: The subjects of group A and group C receive boxes containing placebo for supplementation for a total of 12 weeks.
Study NCT04641533 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: L-PRF + DPSC
Description: After surgical removal of impacted mandibular third molars, extraction sockets were filled with L-PRF membranes + DPSCs.
Study NCT04641533 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: L-PRF
Description: After surgical removal of impacted contralateral mandibular third molars, each extraction sockets were only filled with L-PRF membranes.
Study NCT02910726 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel Lymph Node Biopsy
Study NCT02910726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indocyanine green (ICG)
Study NCT00370097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLOVENT (fluticasone propionate) HFA
Description: FLOVENT HFA consists of a white to off-white suspension of FP (micronized) in a liquefied hydrofluoroalkane propellant, 1,1,1,2-tetrafluoroethane. Subject will receive FP HFA using an Aerochamber Plus with Infant Mask.
Study NCT00370097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo HFA
Description: Subjects will receive FP-matched placebo using an Aerochamber Plus with Infant Mask.
Study NCT00783328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00299804
Description: Dosage form: 5 mg and 20 mg tablet Dosage: 15 mg, 30 mg and 45 mg, orally, once daily Number of Cycles: until progression or unacceptable toxicity develops.
Study NCT03170609 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multivalent group B streptococcus vaccine
Description: Various formulations at three dose levels
Study NCT03170609 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline Control
Study NCT02735473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Choline bitartrate
Study NCT02735473 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01979237 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SPASO method and FARES method
Description: SPASO method and FARES method as shoulder dislocation reduction methods
Study NCT01900860 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Three different doses of vitamin D will be administered in a double-blinded fashion. The three doses are 400, 4000, or 10,000 IU/day
Study NCT00032630 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Coronary artery bypass - on-pump
Description: CABG procedure performed on heart lung machine
Study NCT00032630 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Coronary artery bypass - off-pump
Description: CABG procedure performed without the use of the heart lung machine
Study NCT02237040 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mandibular manipulation technique
Description: patients are treated with The mandibular manipulation technique reported by Farrar, which was an effective treatment method to reset the physiological positional relationship between condyle and disc.Then patients are told to persist in mouth opening training at home everyday. The mouth opening training is performed as follow: patients are told to try to close his mouth in intercuspal position at first, then open their mouth as wide as possible(the reference maximal mouth opening is as wide as the mouth opening after treatment in last time), then close back to the intercuspal position again.
Study NCT00701571 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Virtual Reality distraction
Description: Virtual Reality involves the participant wearing a helmet with sight and sound. the visual provided is a type of immersive video game, the game used is Snow World. In some cases the participant will be exposed to 3D representation of the game, and in other cases a lower tech version with less immersive qualities.
Study NCT00543998 — intervention group
Intervention type: DEVICE
Intervention: Optical Measurement transillumination
Description: Optical Measurement of sinus
Study NCT01880905 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Measure of uteroovarian ligament length during gynecological surgery
Study NCT00350779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin
Description: Sitagliptin 100mg tablet each day for 54 weeks. All subjects will be given placebo to sitagliptin for a 2 week period.
Study NCT00350779 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Placebo to sitagliptin 100mg tablet each day for 54 weeks.
Study NCT00350779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosiglitazone
Description: Subjects taking 4mg or greater rosiglitazone at screening will enter a 6 week stable dose period followed by a 54 week treatment period. Subjects who are taking less than 4mg/day or no rosiglitazone at screening will be titrated to a stable dose of at least 4mg over a a maximum of 8 weeks followed by a dose stable period of up to 12 weeks then a 54 week treatment period. Total treatment will be up to 77 weeks.
Study NCT00350779 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: rosiglitazone
Description: Subjects taking 4mg or greater rosiglitazone at screening will enter a 6 week stable dose period followed by a 54 week treatment period. Subjects who are taking less than 4mg/day or no rosiglitazone at screening will be titrated to a stable dose of at least 4mg over a a maximum of 8 weeks followed by a dose stable period of up to 12 weeks then a 54 week treatment period. Total treatment will be up to 77 weeks.
Study NCT00350779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Subjects taking 1500mg or greater metformin at screening will enter a 6 week stable dose period followed by a 54 week treatment period. Subjects who are taking less than 1500mg/day or no metformin at screening will be titrated to a stable dose of at least 1500mg over a a maximum of 8 weeks followed by a dose stable period of up to 12 weeks then a 54 week treatment period. Total treatment will be up to 77 weeks.
Study NCT00350779 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: metformin
Description: Subjects taking 1500mg or greater metformin at screening will enter a 6 week stable dose period followed by a 54 week treatment period. Subjects who are taking less than 1500mg/day or no metformin at screening will be titrated to a stable dose of at least 1500mg over a a maximum of 8 weeks followed by a dose stable period of up to 12 weeks then a 54 week treatment period. Total treatment will be up to 77 weeks.
Study NCT00350779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glipizide
Description: Subjects not meeting specific glycemic controls during the 54-week treatment period will use glipizide as rescue therapy. Glipizide will be titrated in 5mg doses up to a maximum 40mg each day. (In Canada, the rescue therapy will be a sulfonylurea agent marketed in that country.)
Study NCT00350779 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: glipizide
Description: Subjects not meeting specific glycemic controls during the 54-week treatment period will use glipizide as rescue therapy. Glipizide will be titrated in 5mg doses up to a maximum 40mg each day. (In Canada, the rescue therapy will be a sulfonylurea agent marketed in that country.)
Study NCT00280813 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Treatment in Addiction Recovery (STAR)
Study NCT02152215 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acellular dermal matrix membrane
Description: The surgical procedure will consist of a full-thickness papilla preservation flap performed on the buccal and a full thickness flap on the palatal to expose the alveolar ridge and the tooth to be extracted. The group will receive an intrasocket cancellous particulate allograft plus a facial overlay graft using a bovine xenograft covered by an acellular dermal matrix, composed of human connective tissue matrix.
Study NCT02152215 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Polylactic acid membrane
Description: The surgical procedure will consist of a full-thickness papilla preservation flap performed on the buccal and a full thickness flap on the palatal to expose the alveolar ridge and the tooth to be extracted. The group will receive intrasocket cancellous particulate allograft plus a facial overlay graft using a bovine xenograft, covered by a bioabsorbable membrane made of polylactic acid and a citric acid ester
Study NCT04370535 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PMA-zeolite
Description: The subjects of group B and group D receive boxes containing PMA-zeolite for supplementation for a total of 12 weeks.
Study NCT00336336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: n-3 PUFA
Description: 1 g die per os
Study NCT00821015 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation with cryoballoon catheter
Description: For each patient, the balloon catheter will be advanced to the ostium of each pulmonary vein. Once location has been optimized, the balloon will be inflated, and cryoenergy delivery will be initiated. Because the entire surface of the balloon acts as an ablative surface, circumferential ablation of each pulmonary vein will be achieved concurrently. This will be completed for each pulmonary vein for each patient.
Study NCT00784056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactic Acid (Dermacyd PH_DETINLYN Tangerine Mix)
Description: Lactic Acid (Dermacyd PH_DETINLYN Tangerine Mix)
Study NCT01349127 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 20µg Vitamin D3
Description: 20µg (800IU) of vitamin D3/day for 12-weeks while lactating, commencing 10-14 days post-partum.
Study NCT01349127 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 20µg Vitamin D3 + 500 mg Calcium
Description: 20µg (800IU) of vitamin D3 + 500mg calcium carbonate/day for 12-weeks while lactating, commencing 10-14 days post-partum.
Study NCT01349127 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One gelatin placebo capsule containing zero vitamin D3 taken for 12-weeks while lactating, commencing 10-14 days post-partum.
Study NCT03406624 — intervention group
Intervention type: PROCEDURE
Intervention: Biopsy
Description: Biopsies will be taken from disc and / or endplates during elective lumbar fusion surgery or disc herniation surgery (endplate biopsy is omitted in disc herniation surgery)
Study NCT00336336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: 10 mg die per os
Study NCT03230838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftolozane/Tazobactam
Description: 12 to \<18 years of age: Ceftolozane 1 g/dose; Tazobactam 0.5 g/dose via a 60-minute (±10 minutes) IV infusion every 8 hours for 7-14 days. \<12 years of age: Ceftolozane 20 mg/kg with Tazobactam 10 mg/kg (not to exceed Ceftolozane 1 g and Tazobactam 0.5 g) via a 60-minute (±10 minutes) IV infusion every 8 hours for 7-14 days.
Study NCT03230838 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Description: Meropenem 20 mg/kg (maximum 1 g/dose) administered IV every 8 hours for between 7 to 14 days.
Study NCT00336336 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 gram c. per os
Study NCT02676635 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ergonomics training and/or Safety Voice training
Description: Ergonomics training will focus on ergonomic principles specific to masonry such as goals of ergonomics, common musculoskeletal disorders among masons, modifiable work factors and risk factors, hazard analysis, hierarchy of controls, and current ergonomic solutions for masonry. Safety Voice training will focus on development of skills such as self-direction, self-control, accountability, responsibility, communication strategies, and leadership that can help them to develop a safety voice about safety in general, and ergonomics specifically.
Study NCT00336336 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 mg c. per os
Study NCT01077102 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Eccentric exercise training
Description: The eccentric exercise training will be performed using a specially built cycle ergo meter where the pedals are driven in backward direction by an electric motor, which has to overcome the adjustable resistance of the electromagnetic brake. During eccentric cycle ergometry patients have to resist the turning pedals.
Study NCT01077102 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eccentric exercise training
Description: The eccentric exercise training will be performed using a specially built cycle ergo meter where the pedals are driven in backward direction by an electric motor, which has to overcome the adjustable resistance of the electromagnetic brake. During eccentric cycle ergometry patients have to resist the turning pedals.
Study NCT01516645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK2898
Description: injection
Study NCT04282720 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: SurgiMend Mesh
Description: Following placement of SurgiMend mesh during laparoscopic hiatal hernia repair, patient will be scheduled for follow up using an upper GI series to check for recurrence of the hiatal hernia. Follow up upper GIs will be performed at 6 months post-surgery. Subjects will also complete a QOL survey to assess other GI associated symptoms before and after surgical repair. The QOL survey can be administered by phone by study team members
Study NCT01714856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole hydrochloride CR 2mg Tablets
Description: Ropinirole is an orally administered non-ergoline dopamine agonist. Ropinirole is indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease.
Study NCT03713996 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for insomnia
Description: CBT-I is designed to change sleep habits as well as direct misconceptions about sleep and insomnia. Participants will receive several face-to-face interview techniques: sleep restriction therapy, stimulus control procedures, sleep hygiene, relaxation training and cognitive components. The intervention will be provided in 6-session (one session/week).
Study NCT03713996 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Participants in this arm will receive education in sleep hygiene, foot care, causes and diagnosis of diabetes, healthy diet, and physical activity. The education will be provided in 6-session (1 session/week).
Study NCT01368887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DPS-102
Description: The patient will apply the treatment twice daily in the morning and at bedtime on the involved area only. The scheduled treatment duration is 12 weeks. Patient to begin treatment on the night of Visit 1.
Study NCT01368887 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle / Placebo
Description: The patient will apply the vehicle twice daily in the morning and at bedtime on the involved area only. The scheduled treatment duration is 12 weeks. Patient to begin treatment on the night of Visit 1.
Study NCT01368887 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcipotriol Monotherapy
Description: The patient will apply the treatment twice daily in the morning and at bedtime on the involved area only. The scheduled treatment duration is 12 weeks. Patient to begin treatment on the night of Visit 1.
Study NCT02382523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acthar 80 unit injection
Description: Subjects not responding after 3 months of therapy (increasing creatinine; proteinuria not lower by 30%), will continue therapy at a dose 120 U SC x2/wk. Treatment will be discontinued if improvement is not observed 6 months after initiation of therapy.~If partial remission is achieved with Acthar 80 U SC x2/wk or x3/wk then Acthar will be increased to 120 U SCx2/wk; if remission is achieved, treatment will be continued at this dose for a total of 12 months; otherwise, if response is not observed after 3 months of treatment with the higher dose, we will resume therapy with the original dose/schedule. We will check anti-ACTH antibodies in non-responders.~If relapse occurs during the follow-up period, a 6 month treatment with Acthar at 120 U SC x2/wk will be started (not for partial responders), and the response will be assessed.
Study NCT02920255 — intervention group
Intervention type: OTHER
Intervention: Diagnostic
Description: Measurement of spinal tilt
Study NCT01507077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZGN-440
Description: Subjects will receive ZGN-440 twice-weekly over a 4-week treatment period for a total of 8 doses. A range of doses will be evaluated.
Study NCT01507077 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ZGN-440 sterile diluent
Description: Subjects will receive placebo twice-weekly over a 4-week treatment period for a total of 8 doses. A range of doses will be evaluated.
Study NCT03042299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-536
Description: TAK-536 granules.
Study NCT03042299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-536
Description: TAK-536 tablet.
Study NCT00750451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low molecular weight heparin (enoxaparine sodium)
Description: 1 mg/kg/day subcutaneously in the luteal phase after IVF treatment
Study NCT00750451 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: crinone 8% gel
Description: routine luteal phase support with progesterone gel
Study NCT03288077 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tryptophan
Description: Beverage including tryptophan
Study NCT02885792 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Illness history
Description: Existing psychiatric and somatic diagnosis and treatment. Charlson co-morbidity Index.
Study NCT02885792 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Measure of social conditions
Description: A self-report questionnaire measuring social isolation, including relations to family and friends.
Study NCT02885792 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Measure of psychiatric condition
Description: This method measures symptom severity, therapeutic response and general improvement, suicidal ideation, cognitive insight and awareness of illness and need for treatment and the ability to relabel symptoms.
Study NCT02885792 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiovascular measurement
Description: This procedure is used to detect early identification of cardiovascular disease progression.
Study NCT02885792 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiovascular measurement
Description: This procedure is used to detect early identification of cardiovascular disease progression.
Study NCT01398462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CWP232291
Description: IV Infusion
Study NCT04692090 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Each class started with a check-in period during which any questions or concerns could be raised, after which the patients were given 5 minutes for seated meditation and 10 minutes for Shavasana (lying down in a restorative position).~The following poses were instructed during the course: standing poses with mountain pose (tadasana), chair pose (utkatasana), extended triangle pose (utthita trikonasana), extended side angle pose (utthita parshvakonasana), warrior 1 (virabhadrasana 1), warrior 2 (virabhadrasana 2) and tree pose (vrikshasana). The intervention was applied twice a week for 10 weeks.